A Review on Phyto-Therapeutic Approaches in Alzheimer’s Disease

Creative Commons License


Journal of Functional Biomaterials, vol.14, no.1, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 14 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.3390/jfb14010050
  • Journal Name: Journal of Functional Biomaterials
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Aerospace Database, Applied Science & Technology Source, BIOSIS, Communication Abstracts, EMBASE, INSPEC, Metadex, Directory of Open Access Journals, Civil Engineering Abstracts
  • Keywords: enzyme inhibitors, metal chelating, neurodegenerative diseases, phytocompounds, polyphenolics
  • Çanakkale Onsekiz Mart University Affiliated: Yes


© 2023 by the authors.Neurodegenerative diseases occur due to progressive and sometimes irreversible loss of function and death of nerve cells. A great deal of effort is being made to understand the pathogenesis of neurodegenerative diseases. In particular, the prevalence of Alzheimer’s disease (AD) is quite high, and only symptomatic therapy is available due to the absence of radical treatment. The aim of this review is to try to elucidate the general pathogenesis of AD, to provide information about the limit points of symptomatic treatment approaches, and to emphasize the potential neurologic effects of phytocompounds as new tools as therapeutic agents for disease prevention, retardation, and therapy. This survey also covers the notable properties of herbal compounds such as their effects on the inhibition of an enzyme called acetylcholinesterase, which has significant value in the treatment of AD. It has been proven that phytopharmaceuticals have long-term effects that could protect nervous system health, eliminate inflammatory responses, improve cognitive damage, provide anti-aging effects in the natural aging process, and alleviate dementia sequelae. Herbal-based therapeutic agents can afford many advantages and can be used as potentially as new-generation therapeutics or complementary agents with high compliance, fewer adverse effects, and lower cost in comparison to the traditional pharmaceutical agents in the fight against AD.